“When you think about people that are working at grocery stores and restaurants, we want to make sure that they can stay in our Montana communities as Montana grows." ...

This randomized, double-blind, placebo-controlled Phase 2 clinical trial is designed to evaluate the safety and efficacy of povorcitinib (INCB54707) in adult patients with prurigo nodularis (PN ...

George D. Yancopoulos, MD, PhD, Board co-Chair, President, and Chief Scientific Officer at Regeneron said, “This approval extends the remarkable ability of Dupixent to transform treatment paradigms ...

Galderma has reported new interim analysis data from the OLYMPIA long-term extension trial of monoclonal antibody Nemluvio for the treatment of moderate-to-severe prurigo nodularis (PN), a chronic ...

Here are some of the largest recent moves: JPMORGAN CHASE & CO removed 1,401,174 shares (-19.8%) from their portfolio in Q1 2025, for an estimated $888,666,586 CAPITAL WORLD INVESTORS removed ...

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps ...

to treat adults with prurigo nodularis (PN). It is not known if DUPIXENT is safe and effective in children with PN under 18 years of age.

Dupilumab (Dupixent), a human monoclonal antibody that inhibits interleukin (IL)-4 and IL-13 signaling, is now approved in the United States for eight diseases, including atopic dermatitis, asthma ...

Galderma has reported new interim analysis data from the OLYMPIA long-term extension trial of monoclonal antibody Nemluvio for the treatment of moderate-to-severe prurigo nodularis (PN), a chronic ...

Addeddate 2011-07-06 02:04:02 Associated-names Stubbs, William, 1825-1901 Bookplateleaf 0004 Call number 28002313 Camera Canon EOS 5D Mark II External-identifier urn:oclc:record:654245528 Foldoutcount ...

Exciting times are ahead in the next few years for the prurigo nodularis treatment market as it is projected to grow to $2.11 billion in 2029, marking a compound annual growth rate CAGR of 5.1%.

Original results from the phase 3 OLYMPIA 1 (NCT04501679) and 2 (NCT04501666) trials demonstrated the safety and efficacy of nemolizumab administered subcutaneously every 4 weeks in 560 patients ...